Ursolic acid potentializes conventional therapy in experimental leishmaniasis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.3390/pathogens9100855 http://hdl.handle.net/11449/207887 |
Resumo: | Ursolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantuminfected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decreasethe toxicity associated to the conventional drugs. |
id |
UNSP_246647a0a011362fb03c6e9ba3a9f2f0 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/207887 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Ursolic acid potentializes conventional therapy in experimental leishmaniasisAmphotericin BCutaneous leishmaniasisGlucantimeLeishmaniasisTherapyVisceral leishmaniasisUrsolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantuminfected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decreasethe toxicity associated to the conventional drugs.Laboratory of Pathology of Infectious Diseases (LIM50) Department of Pathology Medical School of São Paulo University, Av. Dr. Arnaldo, 455Center of Natural and Human Sciences Federal University of ABC (UFABC), Avenida dos Estados 5001Institute of Biosciences São Paulo State University (UNESP) Praça Infante Dom HenriqueInstitute for Advanced Studies of Ocean São Paulo State University (UNESP), Rua João Francisco Bensdorp, 1178Institute of Biosciences São Paulo State University (UNESP) Praça Infante Dom HenriqueInstitute for Advanced Studies of Ocean São Paulo State University (UNESP), Rua João Francisco Bensdorp, 1178Universidade de São Paulo (USP)Universidade Federal do ABC (UFABC)Universidade Estadual Paulista (Unesp)Jesus, Jéssica AdrianaDa Silva, Thays Nicolli FragosoYamamoto, Eduardo SeijiLago, João Henrique G.Laurenti, Márcia DalastraPassero, Luiz Felipe Domingues [UNESP]2021-06-25T11:02:44Z2021-06-25T11:02:44Z2020-10-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1-14http://dx.doi.org/10.3390/pathogens9100855Pathogens, v. 9, n. 10, p. 1-14, 2020.2076-0817http://hdl.handle.net/11449/20788710.3390/pathogens91008552-s2.0-85094106349Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengPathogensinfo:eu-repo/semantics/openAccess2024-09-03T13:18:23Zoai:repositorio.unesp.br:11449/207887Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-09-03T13:18:23Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis |
title |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis |
spellingShingle |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis Jesus, Jéssica Adriana Amphotericin B Cutaneous leishmaniasis Glucantime Leishmaniasis Therapy Visceral leishmaniasis |
title_short |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis |
title_full |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis |
title_fullStr |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis |
title_full_unstemmed |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis |
title_sort |
Ursolic acid potentializes conventional therapy in experimental leishmaniasis |
author |
Jesus, Jéssica Adriana |
author_facet |
Jesus, Jéssica Adriana Da Silva, Thays Nicolli Fragoso Yamamoto, Eduardo Seiji Lago, João Henrique G. Laurenti, Márcia Dalastra Passero, Luiz Felipe Domingues [UNESP] |
author_role |
author |
author2 |
Da Silva, Thays Nicolli Fragoso Yamamoto, Eduardo Seiji Lago, João Henrique G. Laurenti, Márcia Dalastra Passero, Luiz Felipe Domingues [UNESP] |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Federal do ABC (UFABC) Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Jesus, Jéssica Adriana Da Silva, Thays Nicolli Fragoso Yamamoto, Eduardo Seiji Lago, João Henrique G. Laurenti, Márcia Dalastra Passero, Luiz Felipe Domingues [UNESP] |
dc.subject.por.fl_str_mv |
Amphotericin B Cutaneous leishmaniasis Glucantime Leishmaniasis Therapy Visceral leishmaniasis |
topic |
Amphotericin B Cutaneous leishmaniasis Glucantime Leishmaniasis Therapy Visceral leishmaniasis |
description |
Ursolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantuminfected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decreasethe toxicity associated to the conventional drugs. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-10-01 2021-06-25T11:02:44Z 2021-06-25T11:02:44Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.3390/pathogens9100855 Pathogens, v. 9, n. 10, p. 1-14, 2020. 2076-0817 http://hdl.handle.net/11449/207887 10.3390/pathogens9100855 2-s2.0-85094106349 |
url |
http://dx.doi.org/10.3390/pathogens9100855 http://hdl.handle.net/11449/207887 |
identifier_str_mv |
Pathogens, v. 9, n. 10, p. 1-14, 2020. 2076-0817 10.3390/pathogens9100855 2-s2.0-85094106349 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Pathogens |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
1-14 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
repositoriounesp@unesp.br |
_version_ |
1810021413272158208 |